Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...
Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...
The gene-editing technique known as CRISPR is promising to revolutionize medicine. Some researchers are trying to help make it available for people with very rare genetic disorders. A gene-editing ...
Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...
A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...
Intellia Therapeutics (NASDAQ:NTLA) stock tumbled 50% Monday after the company announced it has temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a ...
7d
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has ...
InvestorsHub on MSN
Intellia stock plunges after halting gene therapy trials over safety issue
Intellia Therapeutics (NASDAQ:NTLA) shares plummeted 50% on Monday after the company announced a temporary halt to patient dosing and screening in its Phase 3 trials of nex-z, citing a serious ...
In 2025, we will see AI and machine learning begin to amplify the impact of Crispr genome editing in medicine, agriculture, climate change, and the basic research that underpins these fields. It’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback